BeiGene Reports Second Quarter 2017 Financial Results
Aug 09, 2017 20:01 pm UTC| Business
CAMBRIDGE, Mass. and BEIJING, China, Aug. 09, 2017 -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of...
Sientra® Reports Second Quarter 2017 Financial Results
Aug 09, 2017 20:01 pm UTC| Business
Remains on Track for FDA PMA Supplement Approval by End of 2017 Completed Acquisition of Miramar Labs, Inc. and Secured $50 Million Credit Facility Reached Definitive Settlement with Brazilian Breast Implant Contract...
Aug 09, 2017 20:01 pm UTC| Business
CAMBRIDGE, Mass., Aug. 09, 2017 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today that it achieved a second milestone under its collaboration with Juno Therapeutics, Inc....
Collegium Reports Second Quarter Financial Results and Provides Corporate Update
Aug 09, 2017 20:01 pm UTC| Business
Collegium strengthens leadership team with key additions to executive team and Board of DirectorsXtampza ER prescriptions grow by 34% in the second quarterXtampza ER Notice of Allowance granted and, once issued, will...
Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial Results
Aug 09, 2017 20:01 pm UTC| Business
AUSTIN, Texas, Aug. 09, 2017 -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases...
Conifer Holdings Reports 2017 Second Quarter Financial Results
Aug 09, 2017 20:01 pm UTC| Business
BIRMINGHAM, Mich., Aug. 09, 2017 -- Conifer Holdings, Inc. (Nasdaq:CNFR) (“Conifer” or the “Company”) today announced results for the second quarter ended June 30, 2017. Second Quarter 2017 Highlights (all...
Anthera Announces FDA Orphan Drug Designation for Blisibimod for the Treatment of IgA Nephropathy
Aug 09, 2017 20:00 pm UTC| Business
HAYWARD, Calif., Aug. 09, 2017 -- Anthera Pharmaceuticals (Nasdaq:ANTH) today announced that blisibimod has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of...